Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease

Figure 1

Colonoscopy showing severe ileal serpiginous ulceration and diffuse ileitis (Rutgeerts classification i4) before starting vedolizumab and ustekinumab therapy.